Text Size

Persistence of Efficacy of 0.1% Cyclosporin A Cationic Emulsion in Subjects with Severe Keratitis Due to Dry Eye Disease: A Nonrandomized, Open-label Extension of the SANSIKA Study

Labetoulle M., Leonardi A., Amrane M., Ismail D., Garrigue J.-S., Garhöfer G., de la Maza M.S., Baudouin C.


  • 2018
  • Clinical Therapeutics
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Technology

    Drug Delivery

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, Bicêtre Hospital, AP-HP, Paris-Sud University, Le Kremlin-Bicêtre, France; Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua, Italy; Santen SAS, Evry, France; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; Institute Clinic of Ophthalmology, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; Quinze-Vingts National Ophthalmology Hospital, Paris, France; UPMC University, Paris 6, Vision Institute, INSERM UMRS968, CNRS UMR7210, Paris, France; University of Versailles Saint-Quentin en Yvelines, Versailles, France

Related Publications

Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study

Ishikawa H., Oka K., Inoue H.


Tear Biomarkers of Topical Sirolimus in Meibomian Gland Dysfunction: A Randomized Trial

Zhou L.; Shimizu H.; Togashi Y.; Kirihara T.; Yang Y.; Lam C.T.; Shimada H.; Tong L.


Layer-by-layer tear film measurement in patients with dry eye and meibomian gland dysfunction

Arita R., Takeuchi G., Sasai K., Nakamura M., Akiba M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022